IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.234
EU - Europa 2.156
AS - Asia 1.497
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 9
OC - Oceania 5
SA - Sud America 2
Totale 6.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.202
CN - Cina 1.408
IE - Irlanda 867
FI - Finlandia 321
UA - Ucraina 275
DE - Germania 194
IT - Italia 189
SE - Svezia 129
GB - Regno Unito 73
SG - Singapore 61
FR - Francia 37
CA - Canada 32
RO - Romania 24
BE - Belgio 12
IN - India 12
NL - Olanda 10
RU - Federazione Russa 8
EU - Europa 7
MU - Mauritius 6
AU - Australia 5
CH - Svizzera 5
JP - Giappone 4
PL - Polonia 4
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BG - Bulgaria 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
VN - Vietnam 2
XK - ???statistics.table.value.countryCode.XK??? 2
AR - Argentina 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
NP - Nepal 1
QA - Qatar 1
SA - Arabia Saudita 1
TR - Turchia 1
TW - Taiwan 1
Totale 6.914
Salva come PNG Salva come JPEG
Città #
Dublin 866
Chandler 643
Jacksonville 423
Nanjing 392
Ashburn 278
Boardman 260
Princeton 168
Nanchang 163
Lawrence 159
Beijing 139
Wilmington 121
Shenyang 116
Hebei 110
Changsha 108
Helsinki 103
Medford 101
New York 95
Jiaxing 91
Ann Arbor 79
Shanghai 69
Tianjin 61
Hangzhou 58
Milan 37
Singapore 34
Woodbridge 29
Norwalk 28
Toronto 28
Seattle 26
Pavia 25
Timisoara 22
Washington 20
Los Angeles 17
Fairfield 15
Jinan 13
Brussels 12
Verona 12
Auburn Hills 10
Falls Church 9
Florence 9
Zhengzhou 9
Guangzhou 8
Ningbo 7
Pune 7
Des Moines 6
Taizhou 6
Monmouth Junction 5
Orange 5
Rome 5
Dearborn 4
Fuzhou 4
Gallarate 4
Reston 4
San Francisco 4
Azzano San Paolo 3
Brugherio 3
Canberra 3
Dallas 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
Lugano 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Shijiazhuang 3
Tappahannock 3
Wayne 3
Andover 2
Antony 2
Borås 2
Chicago 2
Dronten 2
Falkenstein 2
Frankfurt am Main 2
Genoa 2
Gießen 2
Haikou 2
Hanoi 2
Kemerovo 2
Krakow 2
Lagos 2
Lanzhou 2
Leawood 2
Manchester 2
Monza 2
Navi Mumbai 2
Paderno Dugnano 2
Paris 2
Richmond 2
Santa Clara 2
Sofia 2
Srbica 2
The Bronx 2
Tokyo 2
Yokohama 2
Almere Stad 1
Ampang 1
Amsterdam 1
Basel 1
Totale 5.132
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 92
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 80
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 79
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 77
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 74
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 73
Blast phase of essential thrombocythemia: A single center study. 72
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 71
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 70
An insidious presentation of splenic marginal zone lymphoma 70
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 70
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 69
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 68
JAK2 (V617F) mutation in healthy individuals 67
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 66
Peripheral intraneutrophil diplococci in a case of meningococcemia. 65
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 64
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 64
Clinical significance of somatic mutation in unexplained blood cytopenia 64
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 61
Cardiovascular events and intensity of treatment in polycythemia vera. 60
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 59
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 59
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 59
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 58
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 58
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 58
Familial chronic myeloproliferative disorders: the state of the art 57
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 57
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 57
Role of the molecular staging and response in the management of follicular lymphoma patients 56
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 56
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 56
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 56
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 56
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 55
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 55
Allelic imbalance in CALR somatic mutagenesis 55
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 55
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 55
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 54
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 54
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 54
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 53
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 53
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 52
Clinical relevance of JAK2 (V617F) mutant allele burden 52
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 50
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 50
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 50
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 50
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 49
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 49
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 48
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 48
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 48
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 48
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 47
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 47
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 47
Mutational status of myeloproliferative neoplasms. 46
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 46
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 46
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 46
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 46
Improving survival trends in primary myelofibrosis: an international study. 46
Mutations and prognosis in primary myelofibrosis 45
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 45
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 45
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 45
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 44
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 44
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 44
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 43
Myelofibrotic transformation in essentialthrombocythemia. Author reply 43
Diagnosis and management of prefibrotic myelofibrosis. 43
LNK mutations in familial myeloproliferative neoplasms. 43
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 42
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 42
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 42
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 42
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 41
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 41
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 41
Somatic mutations of calreticulin in myeloproliferative neoplasms 41
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 41
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 40
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 39
How I treat essential thrombocythemia. 39
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 38
Masked polycythemia vera diagnosed according to WHO and BCSH classification 38
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 37
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 36
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. 35
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 35
Totale 5.280
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.094 0 646 4 50 3 60 18 95 27 146 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022693 9 4 23 11 17 38 6 38 33 38 115 361
2022/20232.091 223 118 21 135 204 169 1 100 992 13 87 28
2023/20241.055 119 170 55 70 96 302 27 66 10 22 76 42
2024/2025268 66 202 0 0 0 0 0 0 0 0 0 0
Totale 7.261